CONSOLIDATED BALANCE SHEETS (in thousands) SEPTEMBER 30, 2021 AND 2020

<u>ASSETS</u>	2021	2020
CURRENT ASSETS:		
Cash and cash equivalents	\$153,628	\$240,561
Assets whose use is limited	335	254,743
Accounts receivable - net Other current assets	622,337 297,632	482,245 252,886
Total current assets	1,073,932	1,230,435
ASSETS WHOSE USE IS LIMITED	4,404,491	3,529,335
OTHER INVESTMENTS	290,641	202,171
PROPERTY AND EQUIPMENT - NET	2,767,468	2,763,025
RIGHT OF USE ASSETS - OPERATING LEASES	92,702	96,601
RIGHT OF USE ASSETS - FINANCE LEASES	16,184	9,383
BENEFICIAL INTEREST IN BOCA RATON REGIONAL HOSPITAL FOUNDATION, INC.	385,508	315,004
GOODWILL	85,217	84,045
OTHER ASSETS	161,554	130,716
TOTAL ASSETS	\$9,277,697	\$8,360,715
LIABILITIES AND NET ASSETS		
CURRENT LIABILITIES:		
Accounts payable	\$48,951	\$68,718
Estimated third-party payor settlements Contract liabilities	<mark>1,714</mark> 218,516	2,615 297,105
Current maturities of long-term debt	22,425	271,465
Operating lease obligations - current portion	22,663	22,409
Finance lease obligations - current portion	6,548	4,097
Accrued wages, salaries and benefits Accrued expenses and other current liabilities	381,468 493,643	346,447 615,641
Total current liabilities	1,195,928	1,628,497
LONG-TERM DEBT	1,717,527	1,449,393
OPERATING LEASE OBLIGATIONS	79,098	81,302
FINANCE LEASE OBLIGATIONS	22,528	18,542
OTHER LIABILITIES	312,448	322,974
Total liabilities	3,327,529	3,500,708
COMMITMENTS AND CONTINGENCIES (see Note 15)		
NET ASSETS:		
Net assets without donor restrictions	5,296,962	4,326,051
Noncontrolling interests	42,422	40,441
Total net assets without donor restrictions Net assets with donor restrictions	5,339,384 610,784	4,366,492 493,515
Total net assets	5,950,168	4,860,007
TOTAL LIABILITIES AND NET ASSETS	\$9,277,697	\$8,360,715

See accompanying notes to consolidated financial statements.

CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands) YEARS ENDED SEPTEMBER 30, 2021 AND 2020

	2021	2020
UNRESTRICTED REVENUES, GAINS AND OTHER SUPPORT:		
Net patient service revenue	\$4,491,598	\$3,760,676
Other operating revenue (see Note 2)	366,387	353,052
• ···· • · · · · · · · · · · · · · · ·		
Total unrestricted revenues, gains and other support	4,857,985	4,113,728
EXPENSES:		
Wages, salaries and benefits	2,318,821	2,113,423
Supplies	827,340	703,216
Administrative and general	1,158,204	1,027,983
Depreciation and amortization	241,237	235,864
Interest	64,669	65,622
Total expenses	4,610,271	4,146,108
INCOME (LOSS) FROM OPERATIONS	247,714	(32,380)
OTHER INCOME:		
Investment income	719,116	243,728
Measurement period adjustments to the inherent contribution of net assets	717,110	(131,025)
without donor restrictions from affiliation		(151,025)
Other loss - net	(6,290)	(1,431)
Total other income	712,826	111,272
EXCESS OF REVENUES OVER EXPENSES BEFORE INCOME		
TAX PROVISION (BENEFIT) AND NONCONTROLLING INTERESTS	960,540	78,892
		, =
INCOME TAX PROVISION (BENEFIT)	6,363	(3,528)
EXCESS OF REVENUES OVER EXPENSES FROM		
CONSOLIDATED OPERATIONS	954,177	82,420
INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS	(29,379)	(22,893)
EXCESS OF REVENUES OVER EXPENSES ATTRIBUTABLE TO		
BAPTIST HEALTH SOUTH FLORIDA, INC. AND AFFILIATES	\$924,798	\$59,527
NET ACCETC WITHOUT DONOR RECTRICTIONS.		
NET ASSETS WITHOUT DONOR RESTRICTIONS:	¢054 177	\$82,420
Excess of revenues over expenses from consolidated operations Noncontrolling interest related to surgery centers	\$954,177 1,312	\$82,420 407
Sale of limited partnership interests	1,312	1,126
Purchase of limited partnership interests	(311)	(107)
Partnership distributions	(29,715)	(22,765)
Contributions used for property and equipment acquisitions	20,266	28,050
Other - net	(165)	281
Changes in pension obligations	26,012	(3,248)
Increase in net assets without donor restrictions	\$972,892	\$86,164

See accompanying notes to consolidated financial statements.

CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS (in thousands) YEARS ENDED SEPTEMBER 30, 2021 AND 2020

	2021	2020
NET ASSETS WITHOUT DONOR RESTRICTIONS:		
Excess of revenues over expenses from consolidated operations	\$954,177	\$82,420
Noncontrolling interest related to surgery centers	1,312	407
Sale of limited partnership interests	1,316	1,126
Purchase of limited partnership interests	(311)	(107)
Partnership distributions	(29,715)	(22,765)
Contributions used for property and equipment acquisitions	20,266	28,050
Other - net	(165)	281
Change in value of pension liability	26,012	(3,248)
Increase in net assets without donor restrictions	972,892	86,164
NET ASSETS WITH DONOR RESTRICTIONS:		
Contributions	38,453	36,311
Contributions from BRRH Foundation	26,583	18,599
Measurement period adjustments to the inherent contribution of		122,754
net assets with donor restrictions from affiliations Restricted income on donor restricted contributions	5 400	2 922
	5,408	2,832
Net assets released from restrictions Other - net	(18,382) 63	(30,645)
S 1-1-1	70,503	(192)
Change in beneficial interest in BRRH Foundation	,	21,110
Provision for uncollectable pledges	(5,360)	(1,372)
Increase in net assets with donor restrictions	117,268	169,397
INCREASE IN NET ASSETS	1,090,160	255,561
NET ASSETS - BEGINNING OF YEAR	4,860,007	4,604,446
NET ASSETS - END OF YEAR	\$5,950,167	\$4,860,007

See accompanying notes to consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) YEARS ENDED SEPTEMBER 30, 2021 AND 2020

Aljanimus to reconsice change in net assets to net each provided by operating activities 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		2021	2020
Aljanimus to reconsice change in net assets to net each provided by operating activities 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	CASH FLOWS FROM OPERATING ACTIVITIES:		
Cash provided by operating activities:	· ·	\$1,090,160	\$255,561
Depectation and amortization 24,1237 2555 Noncana hizes expense 24,947 255 Accretion of Donal premium and issue costs - net (7,143) (8,64 (8,145) (8,145) (1,145) (8,145) (1,145)			
Nonceath leare expenses		241 237	235,864
Deferred mome tax			25,784
Realized gains on sales of securities - net (•		(8,074)
Change in net unrealized gains and losses (296,734) (10,50) (10,10)			(3,407)
Sales of limited partnership interests 131			(120,723)
Purchases of limited partnership interests S. Restaurement period adjustments to the inherent contribution of net assets without donor restrictions from affiliation 29,714 22,7 Noncontrolling interest related to surgery center acquisitions (1,312) (2,0,0) (2			(1,126)
net assets without donor restrictions from allilation 29,714 22,7 Noncontrolling interest related to surgery center acquisitions (1,312) (2,12) Change in beneficial interest in BRRI Foundation (20,012) (21,12) Operating cash flows from finance leases (3,927) (1,42) Loss (gain) on disposal of assets - net (26,012) 3.3 Changes in assets and liabilities: (106,022) (35,022) Net increase in accounts receivable (116,024) (25,58) Net decrease in cacounts payable (17,155) (6,6 Net decrease in cacounts payable (17,155) (6,6 Net decrease in carcined expenses and other liabilities (29,14) 33,7 Net concrease in carcined expenses and other liabilities (25,526) (25,60) Net cash provided by operating activities 311,524 524,2 CASH FLOWS FROM INVESTING ACTIVITIES: 311,524 524,2 CASH FLOWS FROM INVESTING ACTIVITIES: (21) 4 Purchase of investments (30,00) (35,00) Alse of property and equipment purchases (31,00) (30,00)			107
Partnership distributions 29,714 22,7 Noncontrolling interest related to surgery center acquisitions (1,312) (6 Change in breafficial interest in BRRH Foundation (70,503) (2,1) Operating cash flows from finance leases (1,60,12) (3,27) (1,4 Persion leability adjustment (30,60) (3,2) (4,2) (4,2) (5,2) (6,2) (8,9) (8,9) (8,9) (8,9) (8,9) (8,9) (8,9) (8,9) (8,1)			8,271
Noncontrolling interest related to surgery center acquisitions (1,312) (2, Change in hearfelia interest in BRRH Foundation (2,1) Operating cash flows from finance leases (3,27) (3,2) Loss (gain) on disposal of assets net (36,012) (3,2) Pension liability adjustment (26,012) (3,2) Changes in assets and liabilities (1146,294) (52,5) Net increase in accounts receivable (146,004) (52,5) Net decrease in secounts payable (17,155) (6,6) Net decrease in accounts payable (3,13,12) (25,4) Net increase in accounts payable (3,13,12) (25,4) Net increase in accounts payable (3,13,13) (3,13,13) Net increase		20.714	22.765
Change in breneficial interest in BRRHR Foundation (21,10 operating cash flows from finance leases (21,10 operating cash flows from finance leases (21,10 operating cash flows from finance leases (22,10 operating cash flows from finance leases (26,10 operating cash flows from finance leases (26,10 operating cash flows from finance leases) (26,10 operating cash flows from finance leases (26,10 operating cash flows from finance leases) (26,10 operating cash flows from finance leases (26,10 operating cash flows from finance leases flows from finance			22,765 (407)
Operating cash flows from finance leases (3, 30, 27) (3, 40, 20) (3, 30, 27) (3, 40, 20) (3, 30, 27) (3, 40, 20) (3, 30, 27) (3, 40, 20) (3, 20, 20) (3, 20, 20) (3, 20, 20) (3, 20, 20) (3, 20, 20) (3, 20, 20) (3, 20, 20) (3, 20, 20) (40, 20) (5, 20, 20) (80, 80, 80, 80, 80) (80, 80, 80, 80) (80, 80, 80, 80) (80, 80, 80, 80) (80, 80, 80, 80) (80, 80, 80, 80, 80) (80, 80, 80, 80, 80, 80) (80, 80, 80, 80, 80) (80, 80, 80, 80, 80, 80) (80, 80, 80, 80, 80, 80, 80) (80, 80, 80, 80, 80, 80, 80) (80, 80, 80, 80, 80, 80, 80) (80, 80, 80, 80, 80, 80, 80) (80, 80, 80, 80, 80, 80, 80, 80, 80, 80,			(21,110)
Pension liability aljustment (26,012) 3.3 Changes in assets and liabilities: (146,294) (5.25) Net increase in accounts receivable (106,072) (89.8) Net dicrease in accounts payable (101,155) (6.6) Net decrease in intird-party payors settlements (901) (15.5) Net decrease in accounts payable (901) (15.5) Net decrease in accounts payable (901) (15.5) Net decrease in accounts payable (901) (15.5) Net decrease in operating lease liabilities (25.96) (25.6) Net decrease in operating lease liabilities (25.926) (25.6) Net decrease in operating activities 33.021 37.3 Net cash provided by operating activities 311,524 324.2 CASH FLOWS FROM INVESTING ACTIVITIES: (25.60) (25.60) Sales of invited partnership interests (20.2) (20.2) Sales of limited partnership interests (20.2) (20.2) Purchases of investments (6,775,911) (5,557.6) Procease from sales and maturities of investments (6,775,911		, ,	(1,231)
Changes in ascelant labilities: (146.294) (5.25. Net increase in accounts receivable (106.072) (89. Mestine trease in accounts receivable (106.072) (89. Mestine trease in accounts receivable (107.155) (68. Mestine trease in dufter assets (100.072) (89. Mestine trease in accounts payable (101.155) (68. Mestine trease in contract labilities (29.04) (35. Mestine trease in contract labilities (25.026) (25. Mestine trease in contract labilities (25.026) (25. Mestine trease in contract labilities (35.022) 37. Mestine trease in contract labilities (35.022) (35.022) (35.022) (35.022) (35.022) (35.022) (35.022) (3			(1,420)
Net increase in accounts receivable (146,294) (52,5) Net increase in other assets (106,072) (89,6) Net decrease in accounts payable (17,155) (65,6) Net decrease in intrid-party payor settlements (90) (15,5) Net increase in accrued expenses and other liabilities 24,946 33,7,8 Net decrease in correct expenses and other liabilities (25,926) (25,60) Net decrease in correct wages, salaries and benefits 35,021 37,37 Net cash provided by operating activities 311,524 524,2 CASH FLOWS FROM INVESTING ACTIVITIES: 350,820 (36,6) Sales of investor property and equipment (30,820) (36,6) Sales of limited partnership interests (31) (4 Sales of limited partnership interests (6,775,911) (5,557,4 Proceeds from sales and maturities of investments (6,775,911) (5,557,4 Proceeds from sales and maturities of investments (6,91,433) 5,089,2 Proceeds from sales and maturities of investments (6,91,433) 5,089,2 Proceeds from sales and maturities of investments (2,92,00)<		(26,012)	3,248
Net increase in other assets (106,072) (893) Net decrease in accounts payable (17,155) (65) Net decrease in contract payable (17,155) (65) Net decrease in contract payable (901) (13,50) Net increase in accrued expenses and other liabilities (25,26) (25,6) Net (decrease) increase in contract liabilities (78,589) 297,1 Net (decrease) increase in contract liabilities (78,589) 297,1 Net (actoriase) in accrued wages, salaries and benefits 311,524 324,2 Net cash provided by operating activities 311,524 324,2 CASH FLOWS FROM INVESTING ACTIVITIES: 2 2 Purchase of property and equipment (350,820) (326,4 Sale of property and equipment interests (31) (21) Sale of limited partnership interests (31) (1) Queriases of investments (6,975,911) (55,75,911) Purchases of investments (6,91,433) (5,982,92) Net cash used in investing activities 30,000 40,2 CASH FLOWS FROM FINANCING ACTIVITIES. 20		(146 204)	(52,911)
Net decrease in accourts payable (17,155) (65) Net decrease in third-party payor settlements (901) (15,15) Net increase in accourted expenses and other liabilities (25,956) (25,656) Net decrease in operating lease liabilities (78,589) (297,16) Net (accrease) increase in contract liabilities (78,589) 297,1 Net cash provided by operating activities 31,1524 324,2 CASH FLOWS FROM INVESTING ACTIVITIES: *** *** Purchase of property and equipment (350,820) (326,1 (Acquisitions of) De novo surgery centers and retail pharmacies (21) 4 Sales of limited partnership interests (311) (1 Purchases of investments (6,775,911) (5,575,917) Proceeds from sales and maturities of investments (6,09,453) 5,089,2 Net cash used in investing activities 30,000 402,5 CASH FLOWS FROM FINANCING ACTIVITIES: *** (7,5 Cege from sales and maturities of investments 6,691,453 5,089,2 Net cash used in investing activities 30,0000 402,5		. , ,	(89,679)
Net increase in accrued expenses and other liabilities 24,946 33,76 Net decrease in operating lease liabilities (25,926) (25,526) Net (decrease) increase in contract liabilities 35,021 37,8 Net increase in accrued wages, salaries and benefits 35,021 37,8 Net cash provided by operating activities 311,524 524,2 CASH FLOWS FROM INVESTING ACTIVITIES: 33,370 19,6 Purchase of property and equipment 33,370 19,6 (Acquisitions of) De novo surgery certers and retail pharmacies (21) 4 Sales of limited partnership interests (311) (1 Purchases of limited partnership interests (6,775,911) (5,557,91) Proceeds from sales and maturities of investments (6,775,911) (5,557,91) Proceeds from sales and maturities of investments 6,691,453 5,089,2 Net cash used in investing activities 39,9224 77,3,2 CASH FLOWS FROM FINANCING ACTIVITIES: 27,2 7,2 Repayment from issuance of long-term debt 30,000 40,2 Pocceds from issuance of long-term debt 30,000 40,2	Net decrease in accounts payable		(6,948)
Net decrease in operating lease liabilities (25,926) (25,64) Net (decrease) increase in contract liabilities (78,589) 297,7 Net increase in accrued wages, salaries and benefits 35,021 37,8 Net cash provided by operating activities 311,524 524,2 CASH FLOWS FROM INVESTING ACTIVITIES: Selection of property and equipment (350,820) (326,1 Sale of property and equipment (37,370) 19,6 (Acquisitions of) De novo surgery centers and retail pharmacies (21) 4 Sales of limited partnership interests (311) 0,1 Purchases of limited partnership interests (311) (5,57,7 Proceeds from sales and maturities of investments (6,775,911) (5,557,8 Proceeds from sless and maturities of investments (6,775,911) (5,557,8 Net cash used in investing activities (6,775,911) (5,557,8 Proceeds from issuance of commercial paper notes - net (6,775,911) (5,557,8 Repayment from issuance of long-term debt 30,000 40,25 Proceeds from issuance of long-term debt (2,27) (2,5 Repayment of			(1,985)
Net (decrease) increase in contract liabilities (78,589) 297, Net increase in accrued wages, salaries and benefits 35,021 37,8 Net cash provided by operating activities 311,524 524,2 CASH FLOWS FROM INVESTING ACTIVITIES: 2 Purchase of property and equipment (350,820) (326,1 Sale of property and equipment 37,370 19,0 (Acquisitions of) De novo surgery centers and retail pharmacies (21) 4 Sales of limited partnership interests (311) (1 Purchases of limited partnership interests (6,775,911) (5,575,4 Proceeds from sales and maturities of investments (6,775,911) (5,575,4 Proceeds from sales and maturities of investments (396,924) (773,2 CASH FLOWS FROM FINANCING ACTIVITIES: 2 7.2 Contribution restricted for property and equipment purchases 6,202 7.2 Repayment from issuance of commercial paper notes - net (25,000) 40,000 Proceeds from issuance of commercial paper notes - net (27,146) (21,500) Repayment of finance lease obligations (29,714) (22,500)<			33,710
Net increase in accrued wages, salaries and benefits 35,021 37,3 Net cash provided by operating activities 311,524 524,2 CASH FLOWS FROM INVESTING ACTIVITIES: Turn the provided by financing activities 35,0820 6226,1 Sale of property and equipment 37,370 19,6 42,0			(25,643)
Net cash provided by operating activities 311,524 524,20 CASH FLOWS FROM INVESTING ACTIVITIES: 9130,820 (326,136,820) (326,136,82) (326,136,			37,808
CASH FLOWS FROM INVESTING ACTIVITIES: (350,820) (326,130) Purchase of property and equipment (350,820) (326,137) Sale of property and equipment (37,370) 19,6 (Acquisitions of) De novo surgery centers and retail pharmacies (21) 4 Sales of limited partnership interests 1,316 1,1 Purchases of imited partnership interests (6,775,911) (5,775,911) Purchases of investments (6,775,911) (5,775,911) Proceeds from sales and maturities of investments (6,991,453) 5,089,2 Net cash used in investing activities (396,924) (773,3 CASH FLOWS FROM FINANCING ACTIVITIES: Total contribution restricted for property and equipment purchases 6,202 7,5 Repayment from issuance of commercial paper notes - net (75, (75, Proceeds from issuance of commercial paper notes - net (2,277) (2,5 Debt issue costs (2,297) (2,5 Repayment of long-term debt (2,271,465) (21,1, Repayment of inance lease obligations (4,259) (3,1, Partnership distributions (1,533)			
Purchase of property and equipment (350,820) (326,1 Sale of property and equipment 37,370 19,6 Sale of property and equipment (21) 4 Sales of limited partnership interests (1,316 1,316		311,324	324,237
Sale of property and equipment 37,370 19,6 (Acquisitions of) De novo surgery centers and retail pharmacies (21) 4 Sales of limited partnership interests 1,316 1,1 Purchases of limited partnership interests (311) (1 Purchases of limited partnership interests (6,775,911) (5,557,6 Proceeds from sales and maturities of investments (6,775,911) (5,557,6 Net cash used in investing activities 396,924) (773,2 CASH FLOWS FROM FINANCING ACTIVITIES: 50,809,24 (773,2 Contribution restricted for property and equipment purchases 6,202 7,5 Repayment from issuance of commercial paper notes - net (75,2 (75,2 Proceeds from issuance of long-term debt 300,000 402,5 (2,297) (2,5 Repayment of long-term debt (271,465) (21,5 (21,5 (2,297) (2,5 Repayment of long-term debt (271,465) (21,5 (22,7) (2,5 (2,5) Net cash (used in) provided by financing activities (86,933) 35,4 (28,714) (22,7) (25,6		(250,920)	(226 152)
(Acquisitions of) De novo surgery centers and retail pharmacies (21) 4 Sales of limited partnership interests 1,316 1,1 Purchases of limited partnership interests (311) (1 Purchases of limited partnership interests (6,775,911) (5,557,6 Purchases of investments (6,691,453) 5,089,2 Proceeds from sales and maturities of investments (396,924) (773,2 CASH FLOWS FROM FINANCING ACTIVITIES: S (75,2 Contribution restricted for property and equipment purchases 6,202 7,5 Repayment from issuance of commercial paper notes - net (75,5 (75,5 Proceeds from issuance of long-term debt 300,000 402,5 (2,5 Debt issue costs (2,297) (2,5 (2,5 (2,27) (2,5 Repayment of long-term debt (271,465) (21,5 (21,5 (2,27) (2,5 (2,27) (2,5 (2,27) (2,5) (2,1 (2,2,7) (2,5) (2,5) (2,1) (2,5) (3,1) (3,1) (3,1) (3,1) (3,1) (3,1) (3,1)			19,688
Sales of limited partnership interests 1,316 1,1 Purchases of limited partnership interests (311) (1 Purchases of investments (6,775,911) (5,557,6 Proceeds from sales and maturities of investments 6,691,453 5,089,2 Net cash used in investing activities (396,924) (773,3 CASH FLOWS FROM FINANCING ACTIVITIES: Tontribution restricted for property and equipment purchases 6,202 7,3 Repayment from issuance of commercial paper notes - net (75,5 (75,5 Proceeds from issuance of long-term debt 300,000 402,3 Debt issue costs (2,297) (2,5 Repayment of long-term debt (271,465) (21,5 Repayment of finance lease obligations (4,259) (3,1 Partnership distributions (29,714) (22,7 Net cash (used in) provided by financing activities (1,533) 284,6 NET CHANGE IN CASH AND CASH EQUIVALENTS (86,933) 35,4 CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR \$153,628 \$240,501			407
Purchases of investments (6,775,911) (5,557,67) Proceeds from sales and maturities of investments 6,691,453 5,089,2 Net cash used in investing activities (396,924) (773,2 CASH FLOWS FROM FINANCING ACTIVITIES:		1,316	1,126
Proceeds from sales and maturities of investments 6,691,453 5,089,2 Net cash used in investing activities (396,924) (773,3 CASH FLOWS FROM FINANCING ACTIVITIES: Contribution restricted for property and equipment purchases 6,202 7,5 Repayment from issuance of commercial paper notes - net (75,5 (75,5 Repayment of long-term debt 300,000 402,5 Debt issue costs (2,297) (2,5 Repayment of long-term debt (271,465) (21,5 Repayment of finance lease obligations (4,259) (3,1 Partnership distributions (29,714) (22,7 Net cash (used in) provided by financing activities (1,533) 284,6 NET CHANGE IN CASH AND CASH EQUIVALENTS (86,933) 35,4 CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 240,561 205,0 CASH AND CASH EQUIVALENTS, END OF YEAR \$153,628 \$240,5			(107)
Net cash used in investing activities (396,924) (773,32) CASH FLOWS FROM FINANCING ACTIVITIES: 7,5 Contribution restricted for property and equipment purchases (75,5) 6,202 7,5 Repayment from issuance of commercial paper notes - net (75,5) (75,5) (75,5) Repayment from issuance of long-term debt (2,297) (2,5) (2,297) (2,5) (2,297) (2,5) (2,297) (2,5) (2,297) (2,5) (2,1,465) (21,5) (21,5) Repayment of long-term debt (271,465) (21,5) (21,5) Repayment of finance lease obligations (4,259) (3,1) Partnership distributions (29,714) (22,7) (22,7) (25,7)			(5,557,636)
CASH FLOWS FROM FINANCING ACTIVITIES: 6,202 7,3 Contribution restricted for property and equipment purchases 6,202 7,5 Repayment from issuance of commercial paper notes - net (75,5 Proceeds from issuance of long-term debt 300,000 402,5 Debt issue costs (2,297) (2,5 Repayment of long-term debt (271,465) (21,5 Repayment of finance lease obligations (4,259) (3,1 Partnership distributions (29,714) (22,7 Net cash (used in) provided by financing activities (1,533) 284,6 NET CHANGE IN CASH AND CASH EQUIVALENTS (86,933) 35,4 CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 240,561 205,6 CASH AND CASH EQUIVALENTS, END OF YEAR \$153,628 \$240,5			
Contribution restricted for property and equipment purchases 6,202 7,5 Repayment from issuance of commercial paper notes - net (75,5 Proceeds from issuance of long-term debt 300,000 402,5 Debt issue costs (2,297) (2,5 Repayment of long-term debt (271,465) (21,5 Repayment of finance lease obligations (4,259) (3,1 Partnership distributions (29,714) (22,7 Net cash (used in) provided by financing activities (1,533) 284,6 NET CHANGE IN CASH AND CASH EQUIVALENTS (86,933) 35,4 CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 240,561 205,0 CASH AND CASH EQUIVALENTS, END OF YEAR \$153,628 \$240,5	Net cash used in investing activities	(396,924)	(773,398)
Repayment from issuance of commercial paper notes - net (75,5) Proceeds from issuance of long-term debt 300,000 402,5) Debt issue costs (2,297) (2,5) Repayment of long-term debt (271,465) (21,5) Repayment of linance lease obligations (4,259) (3,1) Partnership distributions (29,714) (22,7) Net cash (used in) provided by financing activities (1,533) 284,6 NET CHANGE IN CASH AND CASH EQUIVALENTS (86,933) 35,4 CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 240,561 205,0 CASH AND CASH EQUIVALENTS, END OF YEAR \$153,628 \$240,561			
Proceeds from issuance of long-term debt 300,000 402,5 Debt issue costs (2,297) (2,5 Repayment of long-term debt (271,465) (21,5 Repayment of finance lease obligations (4,259) (3,1 Partnership distributions (29,714) (22,7 Net cash (used in) provided by financing activities (1,533) 284,6 NET CHANGE IN CASH AND CASH EQUIVALENTS (86,933) 35,4 CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 240,561 205,6 CASH AND CASH EQUIVALENTS, END OF YEAR \$153,628 \$240,5		6,202	7,554
Debt issue costs (2,297) (2,5 Repayment of long-term debt (271,465) (21,5 Repayment of finance lease obligations (4,259) (3,1 Partnership distributions (29,714) (22,7 Net cash (used in) provided by financing activities (1,533) 284,6 NET CHANGE IN CASH AND CASH EQUIVALENTS (86,933) 35,4 CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 240,561 205,6 CASH AND CASH EQUIVALENTS, END OF YEAR \$153,628 \$240,5		300,000	(75,500) 402,985
Repayment of long-term debt (271,465) (21,58) (21,58) (21,58) (3,19) (3,19) (3,19) (3,19) (22,714) <td>· ·</td> <td> ,</td> <td>(2,935)</td>	· ·	,	(2,935)
Partnership distributions (29,714) (22,7 Net cash (used in) provided by financing activities (1,533) 284,6 NET CHANGE IN CASH AND CASH EQUIVALENTS (86,933) 35,4 CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 240,561 205,6 CASH AND CASH EQUIVALENTS, END OF YEAR \$153,628 \$240,5			(21,595)
Net cash (used in) provided by financing activities (1,533) 284,6 NET CHANGE IN CASH AND CASH EQUIVALENTS (86,933) 35,4 CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 240,561 205,6 CASH AND CASH EQUIVALENTS, END OF YEAR \$153,628 \$240,5	• •		(3,124)
NET CHANGE IN CASH AND CASH EQUIVALENTS (86,933) 35,4 CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 240,561 205,0 CASH AND CASH EQUIVALENTS, END OF YEAR \$153,628 \$240,50	Partnership distributions	(29,714)	(22,765)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR CASH AND CASH EQUIVALENTS, END OF YEAR \$153,628 \$240,501	Net cash (used in) provided by financing activities	(1,533)	284,620
CASH AND CASH EQUIVALENTS, END OF YEAR \$153,628 \$240,5	NET CHANGE IN CASH AND CASH EQUIVALENTS	(86,933)	35,479
	CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	240,561	205,082
	CASH AND CASH EQUIVALENTS, END OF YEAR	\$153,628	\$240,561
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:	SLIDDI EMENTAL DISCLOSLIDES OF CASH ELOW INFORMATION:		
		\$69.641	\$68,152
			\$1,089
SUPPLEMENTAL DISCLOSURES OF NON-CASH OPERATING	SUPPLEMENTAL DISCLOSURES OF NON-CASH OPERATING		
AND FINANCING ACTIVITIES:			
			(\$7,192)
Beginning operating lease right of use asset balance (\$103,3	Beginning operating lease right of use asset balance	(\$22,365)	(\$27,085) (\$103,303) \$103,303

See accompanying notes to the condensed consolidated financial statements.